ABOUT KALOCYTE
KaloCyte, Inc., a pre-clinical stage healthcare biotech startup company, is located at the University of Maryland, Baltimore (UMB) as an Affiliate of the UM BioPark. KaloCyte’s offices and labs are sited within the UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was incorporated in 2016 by co-founders Dr. Doctor, Dipanjan Pan, PhD and Phil Spinella, MD – expert researchers in physiology, bioengineering, and trauma care. KaloCyte has demonstrated proof of concept for ErythroMer, a dried, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by $14M in NIH and DOD grants and over $5M in investor funding.
KaloCyte History
- Raised additional $0.7M of bridge round
- Team expanded to 10 employees, plus one intern
- Awarded DoD CMRP TTDA grant ($2.5M) for lyophilization optimization
- Subcontract for DARPA FSHARP expanded by $500K
- Maryland Tech Council ICON Awards finalist – Emerging Life Science CEO of the Year
- Qualified Maryland Biotech Company (QMBC) for State Biotech Investment Initiative Tax Credit (BIITC)
- Opened new bridge round, raised $1M
- Grew team to 9 employees, plus one intern
- Awarded NIH Phase 2B grant ($3M) for IND-enabling toxicology studies
- Subcontract for DARPA FSHARP $46M consortium award to UMB ($3.2M to KaloCyte)
- Comcast RISE Award recipient
- Maryland Tech Council ICON Awards finalist – Emerging Life Science Company of the Year
- Qualified Maryland Biotech Company (QMBC) for State Biotech Investment Initiative Tax Credit (BIITC)
- Finalist in the 8th Annual Biohealth Capital Region’s Crab Trap Pitch Event
- Raised $1M convertible note
- Expanded space, scientific team and expertise (total 8 employees); hosted first intern from UM School of Pharmacy (UM-SOP)
- Entered national phase with EM V2 patent filings in 11 target countries/regions
- Filed joint IP with UM for EM clearance system
- Awarded Maryland Industrial Partnerships (MIPS) Phase 2 grant ($100K) with UM-SOM
- Angel Capital Association Summit – Innovation Funders Showcase winner
- PitchForce A-Round – First Place winner
- Raised $1M convertible note
- Expanded scientific team with 2 new scientists (total 5 employees)
- Awarded NIH CRP SB1 grant ($500K)
- Filed and published EM V2 patent (US and PCT)
- Held Pre-IND Meeting with FDA CBER
- Awarded Maryland Industrial Partnerships (MIPS) Phase 1 grant ($100K) with UM-SOM
- Raised $1M convertible note
- Filed provisional patent application for lead candidate, EM V2
- Moved to Baltimore, MD as a University of Maryland (UM) BioPark Affiliate
- Leased lab and office space in new Center for Blood Oxygen Transport & Hemostasis (CBOTH) at UM School of Medicine (UM-SOM)
- Awarded NIH Ph1 SBIR grant ($375K)
- Subaward on Haima Therapeutics’ DoD CDMRP CRRP grant ($1.6M)
- Participated in NIH CAP accelerator program
- Held INTERACT Meeting with FDA
- First seed funding ($800K) equity
- Board of Directors expanded
- First scientists hired
- CEO recruited
- Startup Connection Event: Rubin Brown Award
- American Society Hematology (ASH), awarded “Best of ASH” & press release
- Awarded NIH NHLBI Fast Track STTR grant ($2M)
- Awarded DoD CDMRP grant ($3M)
- KaloCyte, Inc. formed as a Delaware C-Corporation
- Patents issued, ‘Quick Start License’ with WUSTL
- Board of Directors and Scientific Advisory Board form
by Drs. Pan, Doctor & Spinella
at Washington University in St. Louis (WUSTL)
- Bench Pilot Work
Formulation demonstrates key requirements
Novel transfusion models - First in vivo POC
Efficacy for hemorrhagic shock and 70% blood exchange
Formulation ErythroMer (EM) V1 - First Funding & Support
Children’s Discovery Institute OAIF Grant ($1M)
Invention Disclosure (WUSTL)
Bear Cub award ($75K) - Incubator Program: BioGenerator Fundamentals
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by nearly $20M in federal grants and investor funding.